JNJ vs SENS
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.
SENS exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 1/9, indicating critical failures in profitability and operational efficiency. While the company shows impressive top-line revenue growth of 71.80% and maintains a strong liquidity position (Current Ratio 4.83), these are offset by a devastating profit margin of -196.03% and a consistent track record of missing earnings estimates. The stock is in a long-term bearish trend with a 5-year decline of 81.7%, suggesting that the market is discounting the growth in favor of the unsustainable burn rate.
Compare Another Pair
Related Comparisons
JNJ vs SENS: Head-to-Head Comparison
This page compares Johnson & Johnson (JNJ) and Senseonics Holdings, Inc. (SENS) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.